Shots:
- The CHMP has recommended Vevzuo & Denosumab BBL (brand name under approval), biosimilars of Xgeva & Prolia (denosumab)
- Opinion was based on the comprehensive clinical data submitted by Biosimilar Collaborations Ireland (Biocon Biologics’ subsidiary) incl. trials, which showed comparable PK, safety, efficacy & immunogenicity to the reference
- Denosumab is a mAb that works by targeting RANKL which regulates bone metabolism & osteoclast formation
Ref: PRNewswire | Image: Biocon Biologics
Related News:- The US FDA Approves Biocon Biologics’ Jobevne (Biosimilar, Avastin)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
